Lung Cancer |

Correlation of Charlson Comorbidity Index With Venous Thromboembolism in Advanced Lung Cancer FREE TO VIEW

Natalie Berger, MD; Susan Tannenbaum, MD; D. Datta, MD
Author and Funding Information

University of Connecticut Health Center, Farmington, CT

Chest. 2014;146(4_MeetingAbstracts):598A. doi:10.1378/chest.1991227
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters II

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 29, 2014 at 01:30 PM - 02:30 PM

PURPOSE: The incidence of venous thromboembolism (VTE) is reported to be 3% in lung cancer patients, with risk factors for VTE consisting of adenocarcinoma, metastasis and number of chronic medical comorbidities. Whether the Charlson Comorbidity Index (CCI), a predictor of 10-year mortality for patients with comorbidities, correlates with VTE in patients with advanced lung cancer has not been studied. The objective of this study was to determine whether the CCI correlates with occurrence of VTE.

METHODS: Medical Records of 79 adult patients with advanced lung cancer (Stage 3B and4) being treated at our institution’s cancer center over the last 3 years was reviewed. Patient demographics, type of lung cancer and the presence of following comorbid conditions were noted: myocardial infarction,, congestive heart failure, peripheral vascular disease, chronic obstructive pulmonary disease, diabetes (with/without end-organ damage), dementia, cerebrovascular disease, hemiplegia, peptic ulcer disease, AIDS, chronic renal failure, chronic liver disease(mild, moderate/severe), other non-metastatic tumor, leukemia or lymphoma and connective tissue disease. CCI was calculated based on above parameters, with age factored in, using an online calculator. Number of patients who had developed VTE was determined. Univariate analysis was performed to determine whether CCI was associated with VTE. Correlation of CCI with VTE was determined by calculating Pearson’s coefficient. p< 0.05 was deemed statistically significant.

RESULTS: Mean age of studied patient was: 70 ± 13years; 49% were males; 73% had adenocarcinoma, 12% had squamous cell and 15% small cell cancer. Sixteen patients (20%) developed VTE. Mean CCI for all subjects was 10. Mean CCI was 9 for patients with VTE and 10 for patients without VTE (p= 0.62). No significant correlation was found between CCI and the occurrence of VTE (r =0.08; p=0.23).

CONCLUSIONS: CCI doesnopt correlate with the occurrence of VTE on patients with advanced lung cancer.

CLINICAL IMPLICATIONS: Though the number of chronic medical comorbidities present has been identified as a risk factor for developing VTE in patients with lung cancer, the Charlson Comorbidity Index (CCI) does not correlate with the occurrence of VTE in patients with advanced lung cancer. This should be reassessed in a larger study.

DISCLOSURE: The following authors have nothing to disclose: Natalie Berger, Susan Tannenbaum, D. Datta

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543